Cabaletta Bio CABA 深 滬
等待開盤 11-04 09:30:00 美东时间
3.01
-0.600
-16.62%
華盛通- 最 高3.575
- 今 開3.56
- 成交量 1164.92万股
- 最 低 2.75
- 昨 收 3.61
- 總市值 2.75亿
- 52周最高 5.46
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 0.9857
- 委 比 28.96%
- 總股本 9146.52万
- 歷史最高 26.35
- 量 比 1.24
- 振 幅 22.85%
- 歷史最低 0.59
- 每 手 1
- 風險率 0.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 苹果、亚马逊、Cloudflare、西部数据、Twilio等获十多家机构集体上调目标价；杰富瑞首予Cloudflare"持有"评级，目标价250美元
今日重点评级关注：康托·菲茨杰拉德：维持Cabaletta Bio"超配"评级，目标价从15美元升至30美元；HC Wainwright & Co.：维持Invivyd"买入"评级，目标价从5美元升至10美元
11-03 20:20
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Cabaletta Bio (NASDAQ:CABA) shares rose 36.6% to $3.38 during Friday's...
11-01 01:06
Cabaletta Bio Announces Clinical Data And Development Updates Across RESET-Myositis, RESET-SSc And RESET-SLE Trials Evaluating Rese-Cel
– All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who met key registrational inclusion criteria exceeded the registrational primary endpoint, demonstrating major TIS responses with no
10-27 19:10
Cabaletta Bio Presents Positive Clinical Data and Development Updates for Rese-cel at ACR Convergence 2025
Cabaletta Bio announced positive clinical data for rese-cel in treating patients with myositis, systemic sclerosis (SSc), and lupus. In the Phase 1/2 DM/ASyS cohort, all patients meeting inclusion criteria achieved major clinical responses without immunomodulators. A registrational trial for DM/ASyS is planned with 14 patients and a 16-week endpoint. In SSc, all patients with sufficient follow-up showed transformative responses off immunomodulato...
10-27 11:00
High Tide Celebrates Four Years of the Cabana Club
The Company Raises Its Long-Term Targets to 3 Million Cabana Club Members and 350 Canna Cabana Locations Across Canada Canna Cabana Named Canada's Most Recognizable Cannabis Retailer CALGARY...
10-21 20:00
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
Cabaletta Bio appoints Steve Gavel as Chief Commercial Officer, who brings extensive CAR T experience from Legend Biotech. Gavel will lead global commercial strategy for rese-cel, with a BLA submission expected in 2027. He previously led the successful launch of CARVYKTI® at Legend Biotech and has a strong track record in commercializing cell therapies. The company anticipates Gavel's leadership will enhance the commercialization efforts for rese...
10-14 12:00
Analysts’ Top Healthcare Picks: Cabaletta Bio (CABA), Icon (ICLR)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
10-14 01:50
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
10-13 11:26
Cabaletta Bio Presents Promising RESET-PV Trial Data
Cabaletta Bio ( ($CABA) ) has shared an announcement. On October 9, 2025, Cabal...
10-10 00:28
Cabaletta Bio Reports Initial Results For Rese-cel In Pemphigus Vulgaris Without Preconditioning; Shows Complete B Cell Depletion, Rapid Reduction In Autoantibodies And Near-complete Resolution Of Clinical Symptoms In Two Of Three Refractory Patients
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators since infusion and
10-10 00:11
